20 October 2002
Qatar has become the latest GCC country to introduce UPRIMA, a revolutionary oral medication for the treatment of erectile dysfunction. The launch took place at a lecture entitled ‘Erectile Difficulties: Understanding the Problem’ at the Intercontinental Hotel, Doha on October 16th. Attended by over 150 doctors and healthcare professionals, the seminar was addressed by Dr. Elfadil M A Elmalik, Consultant Urological and Transplant Surgeon, Hamad Hospital, Qatar.
The drug has already been launched in UAE, Bahrain, Oman, Saudi Arabia and Kuwait. Uprima (apomorphine hydrochloride) is the only centrally acting oral therapy to be approved by the European Commission for the first-line treatment of ED. Uprima is proven to work much faster than its competitors, and with fewer side effects.
“ED is a medical condition affecting more than 150 million worldwide,” said Dr. Elfadil, “It is not a life threatening illness, but it can cause a lot of damage to relationships. There is a lack of knowledge regarding this very sensitive medical condition and many patients suffer for years without seeking a medical opinion. 80% of patients suffer from mild to moderate ED, which is more of a difficulty than a dysfunction.”
He added that ED was a mirror of coronary artery disease and that 70% of ED patients were liable to develop heart disease.
“Uprima is a small tablet that dissolves quickly when placed under the tongue, typically producing an erectile response in under 20 minutes,” explained Amer Haddadin, Product Manager, Abbott Laboratories. “It offers several benefits for patients; it works fast and it works similarly to the way men normally have erections.”
He added that Uprima was most effectively used to treat mild to moderate ED. He pointed out that most couples find Uprima work best after taking it 4-6 times.
“Every patient is different, and Uprima’s unique product attributes allow doctors to provide therapy that meets the needs of individual patients. Uprima encourages spontanaeity while also offering peace of mind to both doctor and patient regarding its safety.”
Speaking about the launch in Qatar, Ibrahim Aql, GM, Abbott Laboratories Gulf region said, “We are thrilled with the success of Uprima across the Gulf region, and we look forward to a very positive response in Qatar. Abbott Laboratories is committed to improving people’s lives through creating innovative health solutions.”
Mr. Ahmed Khalil Al Baker of Al Baker Trading Establishment, the Qatar distributor for Abbott Laboratories, added, “We are excited to be responsible for Uprima in Qatar, as it promises to be very successful because of the widespread nature of this problem.”
Uprima works in the brain to improve diminished erectile function by enhancing the natural signal following stimulation, similar to the way men normally have erections. The treatment works through the central nervous system, producing a series of events that enhances the ability to achieve and maintain penile erection.
Uprima has been extensively studied in clinical trials involving more than 5,000 patients, with more than 120,000 doses of Uprima administered.
ENDS
For further information, please contact Lorraine Chandler/Ghada Kammoun,
phone 971 4 2219065/ mob 971 50 5532817, fax 9714 2247839,Email: lorraine@batespangulf.com
Qatar has become the latest GCC country to introduce UPRIMA, a revolutionary oral medication for the treatment of erectile dysfunction. The launch took place at a lecture entitled ‘Erectile Difficulties: Understanding the Problem’ at the Intercontinental Hotel, Doha on October 16th. Attended by over 150 doctors and healthcare professionals, the seminar was addressed by Dr. Elfadil M A Elmalik, Consultant Urological and Transplant Surgeon, Hamad Hospital, Qatar.
The drug has already been launched in UAE, Bahrain, Oman, Saudi Arabia and Kuwait. Uprima (apomorphine hydrochloride) is the only centrally acting oral therapy to be approved by the European Commission for the first-line treatment of ED. Uprima is proven to work much faster than its competitors, and with fewer side effects.
“ED is a medical condition affecting more than 150 million worldwide,” said Dr. Elfadil, “It is not a life threatening illness, but it can cause a lot of damage to relationships. There is a lack of knowledge regarding this very sensitive medical condition and many patients suffer for years without seeking a medical opinion. 80% of patients suffer from mild to moderate ED, which is more of a difficulty than a dysfunction.”
He added that ED was a mirror of coronary artery disease and that 70% of ED patients were liable to develop heart disease.
“Uprima is a small tablet that dissolves quickly when placed under the tongue, typically producing an erectile response in under 20 minutes,” explained Amer Haddadin, Product Manager, Abbott Laboratories. “It offers several benefits for patients; it works fast and it works similarly to the way men normally have erections.”
He added that Uprima was most effectively used to treat mild to moderate ED. He pointed out that most couples find Uprima work best after taking it 4-6 times.
“Every patient is different, and Uprima’s unique product attributes allow doctors to provide therapy that meets the needs of individual patients. Uprima encourages spontanaeity while also offering peace of mind to both doctor and patient regarding its safety.”
Speaking about the launch in Qatar, Ibrahim Aql, GM, Abbott Laboratories Gulf region said, “We are thrilled with the success of Uprima across the Gulf region, and we look forward to a very positive response in Qatar. Abbott Laboratories is committed to improving people’s lives through creating innovative health solutions.”
Mr. Ahmed Khalil Al Baker of Al Baker Trading Establishment, the Qatar distributor for Abbott Laboratories, added, “We are excited to be responsible for Uprima in Qatar, as it promises to be very successful because of the widespread nature of this problem.”
Uprima works in the brain to improve diminished erectile function by enhancing the natural signal following stimulation, similar to the way men normally have erections. The treatment works through the central nervous system, producing a series of events that enhances the ability to achieve and maintain penile erection.
Uprima has been extensively studied in clinical trials involving more than 5,000 patients, with more than 120,000 doses of Uprima administered.
ENDS
For further information, please contact Lorraine Chandler/Ghada Kammoun,
phone 971 4 2219065/ mob 971 50 5532817, fax 9714 2247839,Email: lorraine@batespangulf.com
© Press Release 2002
